Florida Translational Research Program (FTRP)
|
|
- Shannon Booth
- 8 years ago
- Views:
Transcription
1 Florida Translational Research Program (FTRP) Solicitation of Concept / Assay Development (CAD) Projects for use in Pre-Therapeutic Discovery via High-Throughput Screening (HTS) Purpose of the Program The purpose of the Florida Translational Research Program (FTRP) is to produce a pipeline of potential new medicines based upon laboratory research discoveries. The program provides Florida-based scientists with access to experienced professionals and state-of-the-art technological resources for drug discovery in an effort to facilitate the advancement of potential new drug treatments for today s most prevalent medical needs. The program is funded by the State of Florida through the Florida Department of Health and is administered and executed by Sanford-Burnham Medical Research Institute (SBMRI) at Lake Nona. Executive Summary The purpose of this announcement is to invite Florida-based investigators to join efforts with the Conrad Prebys Center for Chemical Genomics at SBMRI at Lake Nona to develop concepts and assays for high throughput screening (HTS) with the intent of using them to screen for small molecule compounds that show desired properties as pre-therapeutic leads. At the end of the project period, a successful project will have developed one or more HTS-ready assays to identify molecules that affect the biology of interest. Ultimately, this solicitation seeks to establish a stream of scientifically sound and technologically feasible assays for screening by the Conrad Prebys Center for Chemical Genomics at SBMRI. Assays may involve targets indirectly related to disease but which might provide insight into the biology of relevant diseases. Other targets might be associated with rare and neglected diseases. Eligible organizations: Eligibility for this Program is limited to universities, colleges, and non-profit research institutes in the state of Florida. Any individual who is authorized by his or her organization to apply for state and federal grants, and possesses the skills, knowledge, and resources necessary to carry out the proposed research as the project director or principal investigator (PD/PI), is invited to work with his/her organization to develop an application for support. The total number of projects to be selected depends on the scientific merit of applications and the availability of resources within the FTRP. There are no funds associated with selection for the program. The FTRP will support the costs of assay feasibility and development experiments at SBMRI at Lake Nona. There is no limit to the number of applications an applicant may submit under this announcement. Likewise, there is no limit to the number of applications that may be selected from an organization or a PD/PI. Please note the special receipt dates listed under Key Dates. Objective of this Call for Proposals The over-arching objective of this announcement is to invite proposals for the development of innovative biochemical and cell-based assays for biological targets or processes for which there are limited selective and potent small molecule modulators available. Sanford-Burnham Medical Research Institute at Lake Nona Page 1 of 8
2 Guidance for CAD Assay Application This solicitation is divided into two objectives: 1) concept/assay feasibility and development, and 2) configuration of assays for HTS. Proposals are expected to span both aims, although more advanced proposals that are limited in scope to objective 2 will also be considered. Objective 1) Concept / assay feasibility and development. Applications are invited from investigators who, as a result of their independent research efforts, have identified a potential new drug target and who desire to work with SBMRI to develop a cascade of in vitro assays suitable for HTS to identify small molecule modulators of the target of interest. Investigators will collaborate directly with the drug discovery team at SBMRI to review targets, assay concepts, know-how, reagents, and protocols from the investigator s existing portfolio of assays and reagents; to then develop a practical assay concept and work plan to generate the required reagents; and to deliver a workable prototype HTS assay (of at least 384-well format). The professionals at SBMRI may further miniaturize and optimize to a 1536-well format for the purpose of producing pilot HTS data in this final format. The data generated may include confirmation of automated assay robustness (Z >0.5, S/B >4, CV <10%) and pilot screening of a small (~2K compounds) library to establish the approximate hit rate for the primary assay. The team will also develop a plan for a cascade of follow-up assays (orthogonal, counter-screen, selectivity), demonstrate that these assays can support quantitative dose-response studies, and, where possible, generate actual data on pilot hits through this cascade. This solicitation is intended to cover a wide array of potential drug targets. Targets may be any of the three types below: Defined molecular targets (e.g., GPCRs, nuclear receptors, kinases, etc.) Biochemical or cellular pathway targets (e.g., activation of a select phosphorylation cascade) Phenotypic targets (e.g., intracellular translocation of target, neurite extension/retraction, lipid accumulation, etc.) Preliminary data regarding the validation of the target are highly desirable. Such data may be derived from clinical or preclinical observations, and may be obtained from in vitro experiments or in vivo studies. For example, data linking a given target to the pathogenesis of disease using transgenic (knock-out, knock-in, etc.) mice, or obtained from the use of normal and diseased human tissues, are useful in evaluating the therapeutic utility of a compound acting at the proposed target. For this objective, preliminary data regarding the specific assay to be developed are not required or expected. Objective 2) Configuration of assays for HTS. Applications are also invited from investigators who, as a result of their independent research efforts, have identified a potential new drug target and have developed an in vitro assay that requires adaptation and configuration for HTS to identify small molecule modulators of the target of interest. Investigators will collaborate directly with the drug discovery team at Sanford-Burnham to assess the assay, reagents, and protocols from the investigator s existing portfolio; to then develop a practical work plan to generate the required reagents; and to deliver a workable prototype HTS assay (of at least 384-well format). The professionals at Sanford-Burnham may further miniaturize and optimize to a 1536-well format for the purpose of producing generate pilot HTS data in this final format. The data generated may include confirmation of automated assay robustness (Z >0.5, S/B >4, CV <10%) and pilot screening of a small (~2K compounds) library to establish the approximate hit rate for the primary assay. The team will also develop a plan for a cascade of follow-up assays (orthogonal, counter-screen, selectivity), demonstrate that these assays can support quantitative dose-response studies, and, where possible generate actual data on pilot hits through this cascade. Sanford-Burnham Medical Research Institute at Lake Nona Page 2 of 8
3 Areas of interest. Relevant areas of interest include but are not limited to the following: assays for molecular chaperones or molecules that improve the post-translational targeting, folding, or assembly or proteins, especially involving mutant proteins responsible for inborn errors of metabolism, metabolic disorders, cancers, or rare diseases; assays for compounds that modify the function of signaling complexes, regulatory networks, and sorting machinery; biochemical or cell-based assays of activity, behavior, or interaction of proteins (e.g., protein:protein interaction or protein:chromatin interaction) and other molecules of interest; assays of cellular or molecular phenotypes; modulation of expression of genes of interest, including effects on transcription factors, transcription, translation, or RNA splicing; and whole-cell assays that employ engineered cells rendered hypersensitive to a targeted pathway. The following are types of applications that are NOT appropriate for this solicitation: applications for the execution of a screen using an existing HTS-ready assay not requiring assay development for screening, or in which prototype molecules have been identified. Individuals proposing these kinds of activities should apply to the companion solicitations (high-throughput screening [HTS] and hit-to-lead [HTL]) available at the FTRP website ( research focused on understanding normal biology or disease processes; and applications focused on identifying new targets. Assays. Many in vitro biological models are currently used to study biological targets and pathways, to decipher the effects of genetic perturbations on their function, and to establish a possible disease association. These models can be adapted to high-throughput formats for the purpose of screening large collections of compounds with potential biological activity. There are a number of characteristics that make an assay suitable for its adaptation to a high-throughput approach. The assay must be robust and reproducible with a readout that is amenable to automated analysis. In addition, the work proposed must lead to miniaturization of the assay to a 96-well plate (or higher density) format. Further, the assay protocol should be simple enough for automated handling. A broad range of models share many of these features, including biochemical assays, cellular models, and certain model organisms. Emphasis will be placed on novelty of assay approach and novel targets and mechanisms. Appropriate assays might include but are not limited to: biochemical or cell-based assays of activity measuring target interactions involving small molecules, peptides or other biological molecules; cell-based assays measuring cell signaling or the activity of biosynthetic pathways; assays of cellular or molecular phenotypes; modulation of gene expression, including effects on transcription, translation, or RNA splicing; and assays involving mutant proteins associated with disease. Material and Data Sharing. Submitting investigators will be required to provide necessary, unique reagents that are not commercially available such as cells expressing recombinant enzymes/proteins, primary and secondary antibodies, tagged peptide substrates, and available positive controls (e.g., a known inhibitor of the target). Key Dates for this Call for Proposals Call open: March 30, 2015 Sanford-Burnham team available for questions and project mentoring: April-May, 2015 Proposal deadline: Thursday, May 28, 2015, 5:00 p.m. Eastern Awards announced: on or about July 24, 2015 Sanford-Burnham Medical Research Institute at Lake Nona Page 3 of 8
4 Award Information There is no transfer of funds associated with selection of projects for inclusion in the FTRP. Rather, successful applicants will obtain access to resources including assay automation, HTS, and synthetic chemistry capabilities that can be applied to the discovery and development of innovative chemical tools for use in biological research and as platforms for potential therapeutics development. These services will be provided by the Florida State Department of Health through SBMRI at Lake Nona. Eligibility Institutional Eligibility: Eligibility for this program is limited to universities, colleges, and non-profit research institutes in the state of Florida. Investigator Eligibility: Any individual who is authorized by his or her organization to apply for state and federal grants, and possesses the skills, knowledge, and resources necessary to carry out the proposed research as the PD/PI, is invited to work with his/her organization to develop an application for support. Application Requirements All documentation must be formatted with at least ½-inch margins on all sides, using Arial 11 pt font. The PI s name (last name, first name) should appear on the right-hand side of the header on all pages, and pages of the submission beginning with the technical proposal should be numbered sequentially starting at page 1. All applications must contain the following elements: Application Elements Project Narrative Scientific Abstract Technical Proposal Objective 1: Concept / assay feasibility and development Suggested Length 2-3 sentences Limit to 30 lines of text Approximately 3 pages plus references Drug target / pathway description Clinical / experimental evidence linking target and disease Desired mechanism of action of compound Available reagents Objective 2: Configuration of assays for HTS Assay configuration data section (signal intensity, dose-response, reproducibility) Description of proposed secondary and/or counter-screen assays Reagent availability / cost estimate NIH Biosketch Bilateral Confidentiality Agreement (BCA) * Material Transfer Agreement (MTA) References / Publications Limit to 4 or 5 pages per PI PI + co-i(s) (if applicable) No page limit No page limit No page limit Resubmission 2 pages * Please note that only one master BCA per institution is required and will be executed. If one has been executed for your institution, your institutional official should upload a copy of the signed agreement already in place. Additional details, as required, are provided below for each element. Sanford-Burnham Medical Research Institute at Lake Nona Page 4 of 8
5 Project Narrative (no more than 2-3 sentences long). Detail the relevance of the proposed research project to public health. The information should be succinct and in plain language understandable by a general, lay audience. The project narrative is made public for all awarded projects. Scientific Abstract (limit to 30 lines of text). Provide a succinct and accurate description of the proposed work when separated from the application. Include the application s broad, long-term objectives and specific aims, making reference to the public health relevance of the project. Describe concisely the research design and methods for achieving the stated goals. This section should be informative to other persons working in the same or related fields and, insofar as possible, understandable to a scientifically or technically literate reader. Avoid describing past accomplishments and use of the first person. Do not include proprietary, confidential information or trade secrets. If the application is accepted, the project summary / abstract will become public information. Technical Proposal / Project Description (limit to 3 pages not including references). Project Descriptions for Objective 1) Concept / assay feasibility and development should address the following questions: What is the proposed target (e.g., GPCR, kinase, etc.) or mechanism (e.g., PI3K pathway, MAPK pathway, etc.)? In what disease is this target or mechanism implicated and what is the evidence for disease association? What data have you produced that provides the biological rationale underlying the hypothesis that modulation of this target or mechanism will achieve the predicted effects? What would be the site of action of a modulator (e.g., intra-/extracellular, target tissue/organ, etc.)? Comment on what reagents you currently have available or could be readily produced (e.g., proteins, cells, antibodies, etc.). What structural information for the target or the ligand is available? Preliminary data regarding the validation of the target should be included, if available. Project Descriptions for Objective 2) Configuration of assays for HTS should address the following: A description of reagents and readouts currently available to the PI and that can be translated to an automated HTS environment, such as absorbance, fluorescence, luminescence, fluorescence resonance energy transfer (FRET), bioluminescence resonance energy transfer (BRET), biophysical readouts, and cell-based imaging screens, must be included. Assays should be easy to eventually automate and steps such as centrifugation, filtration, and extraction avoided. Assays requiring only addition of reagents, i.e., mix-and-measure assays, are preferable. Generally, the assay protocol should aim to demonstrate a signal of sufficient intensity that it can be easily measured (using for example, a microtiter plate of low volume); reproducible, dose-dependent responses to a small collection of pharmacologically active standards or reaction substrates or inhibitors; and preliminary data indicating baseline values for validation criterion, any kinetic data, and a brief description of the protocols for the current format of assays available. Demonstration that secondary and counter-screen assays are available or can be developed and characterized. Information describing reagent availability, equipment used in configuring the assays, and estimated cost per assay should be provided. Preliminary data regarding the validation of the target are desirable. Such data may be derived from clinical or preclinical observations and may be obtained from in vitro experiments or in vivo studies. For Sanford-Burnham Medical Research Institute at Lake Nona Page 5 of 8
6 example, data linking a given target to the pathogenesis of disease using transgenic (knock-out, knock-in, etc.) mice, or obtained from the use of normal and diseased human tissues, would be useful in evaluating the therapeutic utility of a compound acting at the proposed target. NIH Biosketch (limit of 4 or 5 pages per person). Provide for the PI and co-pi (as necessary). The FTRP will accept biosketches in current NIH format or the new NIH format (as described in NOT-OD ) for this call. Bilateral Confidentiality Agreement (BCA). Must be signed by an authorized institutional official from the Technology Transfer or Sponsored Research office and uploaded to the FTRP website ( prior to submitting all applications. Please note that only one master BCA per institution is required and will be executed. If one has been executed for your institution, your institutional official should upload a copy of the signed agreement already in place. If you do not have an executed agreement in place for your institution, a blank BCA template may be downloaded from the FTRP website. Please check with your institutional official for more information. Material Transfer Agreement (MTA). Must be signed by the PI or other authorized institutional official from the Technology Transfer or Sponsored Research office. This document is available on the FTRP website ( References / Publications (no page limit). Include a list of any publications that support or describe the proposed assays. Resubmission (limit of 2 pages). The resubmission document must contain a numbered, point-by-point statement of how you have responded to the criticisms raised. This statement should not exceed two pages. Highlight the changes to your proposal within the main document either by using the track changes feature in Microsoft Word or by using bold or colored text. To assist you in this task, experts from the Sanford-Burnham team are available for discussion of technical aspects of the proposed approach and to provide guidance on the revision. Contact ftrp@sanfordburnham.org to arrange a conference. Please note that submission of a revised proposal does not guarantee its acceptance. How to Submit Applications Authorized institutional officials must submit applications via the FTRP website ( Prior to submission applicant organizations must register with the FTRP submission website. All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process early to avoid possible delays in submission. All applications must be uploaded to the FTRP portal and submitted by an authorized institutional official following the instructions provided herein. Please note that applications sent by any other means, e.g., hand-carried, postal service mail, commercial carrier, fax, or , will not be considered. For Institutional Officials: To begin, the institutional official must register their organization in the FTRP website. After the institutional official has registered their organization, they can begin creating application packages. Note that registration for previous cycles is sufficient; it is not necessary to register more than one time. Please see the FTRP portal for more information on how to register an organization and assemble application packages. Once registered, the institutional official will have the option to either create applications on behalf of their PIs or can create sub-user accounts for their PIs. Authorized PIs are able to create application cover sheets and upload all required proposal documents; however, only institutional officials are able to officially submit applications on behalf of the organization. If a PI has a sub-user account for access to the portal, the PI is responsible for uploading all required documentation. Once a PI has completed their application package, the institutional official will receive an notifying them that there is a completed application package ready for their review. Institutional officials must review all applications and are responsible for submitting them to FTRP on behalf of the organization by the deadline detailed in this call. Sanford-Burnham Medical Research Institute at Lake Nona Page 6 of 8
7 For PIs: PIs should not attempt to register on the portal or submit proposals on their own. Institutional officials must register the organization in the FTRP portal. PIs should contact the institutional official at their organization and notify them of their interest in applying to the program. All PIs must work with their institutional officials to register with the FTRP submission website to ensure an institutional account is active and the individual PI is affiliated with the account of the applicant organization. Sub-user accounts will allow the PIs access to the portal and will enable them to create and assemble their application packages. Once completed, the PI must use the portal to send their application packages to their institutional officials for review. PIs cannot submit their applications directly to the FTRP. Only an institutional official can submit the application to the FTRP on behalf of the organization after completing a final review of the package. All application packages will be considered works in progress and will not be accepted for evaluation until the institutional official submits the final application package. An acknowledgement of application receipt will be provided to the submitter via . Upon submission, applications will be evaluated for completeness by the FTRP program staff. Applications that are incomplete will not be reviewed. Applicants are strongly encouraged to submit their proposals well in advance of the deadline to ensure they have time to make any corrections that might be necessary for a successful submission. Selection Process Complete applications will be evaluated for technical feasibility and scientific merit by an appropriate review group convened by the FTRP, administered by Sanford-Burnham. Technical Feasibility Review Committee. Evaluate assay proposals for HTS feasibility as configured using the current infrastructure and capabilities of the Conrad Prebys Center for Chemical Genomics at SBMRI at Lake Nona. The panel members will be scientists with sufficient expertise and knowledge to evaluate the technical feasibility of the proposed assay. Assays will receive a simple go/no-go assessment from the committee. Proposals that are determined not to be feasible (no-go) will not be communicated to the Scientific Merit Review Committee. Scientific Merit Review Committee. An external panel of experts, representing universities, government agencies, and private industry outside the state of Florida, evaluates assay proposals for scientific merit, novelty of the target, potential for addressing an unmet medical need, and potential for commercialization. FTRP Steering Committee. Review summary statements from the Scientific Merit Review Committee and develop a balanced portfolio that is consistent with program priorities, existing capacity of the SBMRI Conrad Prebys Center for Chemical Genomics, cost, workload, detection system, etc. Notifications Applicants will be notified of proposal disposition via . These s will contain a written critique of the proposed project. Unsuccessful applicants will be provided with a brief assessment of possible steps to take to improve potential future success. Resubmissions For resubmissions, the committee will evaluate the application as presented in the resubmission documentation, taking into consideration the responses to comments from the previous scientific review group and changes made to the project. As with NIH, applications to the FTRP are limited to two submissions (an original submission and a single revised resubmission). Information on Terms, Conditions, and Required Reports All applicants are required to complete a material transfer agreement (MTA) and confidentiality agreement (BCA) with the SBMRI at Lake Nona. (See page 6 for more details.) Sanford-Burnham Medical Research Institute at Lake Nona Page 7 of 8
8 Submitting investigators will be required to provide necessary reagents such as cells expressing recombinant enzymes/proteins, primary and secondary antibodies, tagged peptide substrates, and available positive controls (e.g., a known inhibitor of the target). Successful applicants must provide 1) a project report to the FTRP within 90 days of project completion and 2) annual updates on long-term FTRP participation success for up to five years post project completion to include grant awards, resulting intellectual property (i.e., patent filings), and related publications. Publications related to the results obtained from the project must acknowledge support by the state of Florida, the Florida State Department of Health, and SBMRI at Lake Nona. Intellectual property inventorship will be determined according to U.S. Patent Office rules and as defined in the material transfer agreement or subsequent inter-institutional agreement. Contacts Scientific and Technical Questions: Layton Harris Smith, Ph.D. Director, Drug Discovery Florida Assistant Professor SBMRI at Lake Nona 6400 Sanger Road Orlando, FL lhsmith@sanfordburnham.org Scientific / Technical and Administrative / Programmatic Questions: Philip Arlen, Ph.D. Associate Director, Outreach, Alliances & Partnerships SBMRI at Lake Nona 6400 Sanger Road Orlando, FL parlen@sanfordburnham.org Administrative and Programmatic Questions: Sonja Gyimah Senior Project Coordinator, Florida Translational Research Program SBMRI at Lake Nona 6400 Sanger Road Orlando, FL sgyimah@sanfordburnham.org Sanford-Burnham Medical Research Institute at Lake Nona Page 8 of 8
Call 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
More informationJ D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H
J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H PURPOSE JDRF, the world s leading non-profit organization
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationJ D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S
J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S PURPOSE JDRF, the world s leading non-profit organization with
More informationMission The mission of the Alliance for Lupus Research is to prevent, treat and cure lupus through medical research.
ALLIANCE FOR LUPUS RESEARCH TARGET IDENTIFICATION IN LUPUS APPLICATION PROGRAM GUIDELINES Effective June 5, 2014 Letter of Intent Due July 10, 2014 APPLICATION DUE DATE August 25, 2014 Applications will
More informationFree to Breathe 2015 Research Grant To Prevent or Stop Lung Cancer Metastasis. Request for Proposals
Free to Breathe 2015 Research Grant To Prevent or Stop Lung Cancer Metastasis Request for Proposals Award Overview Free to Breathe has a new funding opportunity solely focused on research to prevent or
More informationCROHN S & COLITIS FOUNDATION OF AMERICA. Senior Research Award INSTRUCTIONS. Effective September 2013
CROHN S & COLITIS FOUNDATION OF AMERICA Senior Research Award INSTRUCTIONS Effective September 2013 Crohn s & Colitis Foundation of America National Office Research & Scientific Programs Department 733
More informationMultiple Myeloma Research Foundation. 2015 Research Fellow Award. Program Guidelines
Multiple Myeloma Research Foundation 2015 Research Fellow Award Program Guidelines Program Description: MULTIPLE MYELOMA RESEARCH FOUNDATION 2015 RESEARCH FELLOW AWARD The Multiple Myeloma Research Foundation
More informationOnline Submission Deadline: Thursday, October 1, 2015 12:00 Noon, U.S. Eastern Time
Dr. Ralph and Marian Falk Medical Research Trust Awards Programs Transformational Award A program of the Dr. Ralph and Marian Falk Medical Research Trust U.S. Trust, Bank of America N.A., Trustee Online
More informationM110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics
of Biochemistry and Molecular Biology 1. Master the knowledge base of current biochemistry, molecular biology, and cellular physiology Describe current knowledge in metabolic transformations conducted
More informationCell Discovery 360: Explore more possibilities.
Cell Discovery 360: Explore more possibilities. Flexible solutions for the BioPharma laboratory Blood Banking Capillary Electrophoresis Centrifugation Flow Cytometry Genomics Lab Automation Lab Tools Particle
More informationMultiple Myeloma Research Foundation. 2015 Senior Research Award. Program Guidelines
Multiple Myeloma Research Foundation 2015 Senior Research Award Program Guidelines MULTIPLE MYELOMA RESEARCH FOUNDATION 2015 SENIOR RESEARCH AWARD Program Description: The Multiple Myeloma Research Foundation
More informationRE AP QUE PLIC FOR IONS. Compa CPRIT RFA C 12 FORM 2. Company. p.1/17
RE AP QUE ST PLIC AT RFA C 12 FORM 2 FOR IONS Compa any Formation Awards FY 2012 Fiscal Year Award Period September 1, 2011 Augustt 31, 2012 CPRIT RFA C 12 FORM 2 (Rev 6/ /30/11) Company Formation Awards
More informationValidated Cell-Based Assays for Rapid Screening and Functional Characterization of Therapeutic Monoclonal Antibodies
Validated Cell-Based Assays for Rapid Screening and Functional Characterization of Therapeutic Monoclonal Antibodies Abhishek Saharia, Ph. D. Senior Product Manager Validation Assays Drug Discovery Evolution
More informationCURESEARCH FOR CHILDREN S CANCER AND GATEWAY FOR CANCER RESEARCH COMMUNITY IMPACT AWARD - CLINICAL TRIALS
KEY DATES Request for Applications Opens: June 3, 2015 Application Due: August 3, 2015 Award Notification: September 2015 Award Period : October 2015 October 2016 CURESEARCH FOR CHILDREN S CANCER AND GATEWAY
More informationOpen PHACTS Workshop, February 2015. The Lilly Perspective: Challenges We Face & Tools We Need
Open PHACTS Workshop, February 2015 The Lilly Perspective: Challenges We Face & Tools We Need María Jesús Blanco, Ph.D. Director, Advanced Portfolio Strategies Marta Piñeiro-Núñez, Ph.D. Director, Open
More informationProposal Writing in a Nutshell
Proposal Writing in a Nutshell Context Resources http://www.sci.utah.edu/~macleod/grants/ Find Your Purpose Who is the Audience? If you don t know, find out.?? Don t assume too much!! What are Review Criteria?
More informationThe Leading Gene Through Screen CRO
The Leading Gene Through Screen CRO Molecular Biology Services Molecular Biology drives modern drug discovery. Drug screening, target validation and structural biology processes frequently require recombinant
More informationPROGRAM OVERVIEW. Center for Clinical and Translational Research Cancer and Blood Disorders Research Pilot Funds I. PURPOSE
PROGRAM OVERVIEW I. PURPOSE The purpose of the Clinical Program is to cultivate outstanding new research, stimulate preliminary data in novel research directions, and ultimately to launch new nationally-funded
More informationINVESTIGATOR-INITIATED RESEARCH GRANTS
Because breast cancer is everywhere, SO ARE WE. At Susan G. Komen for the Cure, we are committed to ENDING breast cancer forever by ENERGIZING SCIENCE to find the cures and ensuring QUALITY CARE for all
More informationCDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis
CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society
More informationYour partner in immunology
Your partner in immunology Expertise Expertise Reactivity Reactivity Quality Quality Advice Advice Who are we? Specialist of antibody engineering Covalab is a French biotechnology company, specialised
More information2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February
More informationBBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS
BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS 1. The Technology Strategy sets out six areas where technological developments are required to push the frontiers of knowledge
More informationDiabetes and Drug Development
Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin
More informationhttps://syracuseuniversity.qualtrics.com/controlpanel/ajax.php?action=getsurveyprintpre...
Page 1 of 7 SU - UMU Pilot Grant Program Driving Inspiration and Innovation through Collaboration Syracuse University- Upstate Medical University 2015 Pilot Grant Application Responding to society s most
More informationMEMORANDUM OF UNDERSTANDING. ON Research Activities Related to the ToxCast TM Program BETWEEN THE
UNIVERSITY OF MEMORANDUM OF UNDERSTANDING ON Research Activities Related to the ToxCast TM Program BETWEEN THE U.S. ENVIRONMENTAL PROTECTION AGENCY Office of Research and Development National Center for
More informationELITE Custom Antibody Services
ELITE Custom Antibody Services ELITE Custom Antibody Services Experience, confidence, and understanding As a manufacturer and service provider, we have the experience, confidence, and understanding to
More informationINFORMATION FOR GRADUATE STUDENTS IN BIOCHEMISTRY. Department of Chemistry and Biochemistry Utah State University, Logan, Utah
Biochemistry Graduate Program Approved July 2014 INFORMATION FOR GRADUATE STUDENTS IN BIOCHEMISTRY Department of Chemistry and Biochemistry Utah State University, Logan, Utah The Department of Chemistry
More informationDiscovery Grants. 2015-2016 Request for Applications
The mission of the American Brain Tumor Association is to advance the understanding and treatment of brain tumors with the goals of improving, extending and, ultimately, saving the lives of those impacted
More informationSummary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationATIP Avenir Program 2014. Applicant s guide
ATIP Avenir Program 2014 Applicant s guide Important dates: - November 29 th 2013: deadline for the online submission, the mailing of the hard copy of the scientific project, and the letters of recommendation
More informationHigh throughput screening, high content screening, primary and stem cells. new techniques now converging
High throughput screening:layout 1 26/3/09 13:32 Page 25 High throughput screening, high content screening, primary and stem cells new techniques now converging Over the past decade, the use of cell-based
More informationAST Transplantation and Immunology Research Network (TIRN) 2016 Allied Health Professional Research Grant
AST Transplantation and Immunology Research Network (TIRN) 2016 Allied Health Professional Research Grant If you have any questions, please email TIRN@myAST.org. The application deadline is 11:59 pm Pacific
More informationA Guide to the ABTA s 2013 Medical Student Summer Fellowship Application
A Guide to the ABTA s 2013 Medical Student Summer Fellowship Application Please be aware the submission process has changed. All applications for the 2013 American Brain Tumor Association Medical Student
More information2014 Grant Instructions & Policies
2014 Grant Instructions & Policies ELA Research Foundation April 2014 A. INSTRUCTIONS I. SCOPE of RESEARCH Before starting to work on your application, please make sure the scope of your research project
More information2015 Grant Application Guidelines for A Awards
2015 Grant Application Guidelines for A Awards In this packet you will find the following: Award Overview and Eligibility - page 2, 3 Application Information and Outline - pages 4, 5 Important Dates and
More informationChapter 8. Summary and Perspectives
Chapter 8 Summary and Perspectives 131 Chapter 8 Summary Overexpression of the multidrug resistance protein MRP1 confer multidrug resistance (MDR) to cancer cells. The contents of this thesis describe
More informationBiotechnology and Life Science Marketing Services Mailing List and Data Card Order Form
C H I Cambridge Healthtech Institute s Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form Over 800,000 names segmented by scientific interest Featuring U.S and International
More informationPost-Baccalaureate. Research Grants. 2008-2009 request for applications. Because breast cancer is everywhere, so are we.
Because breast cancer is everywhere, so are we. At Susan G. Komen for the Cure, we are committed to ENDING breast cancer forever by ENERGIZING SCIENCE to find the cures and ensuring QUALITY CARE for all
More informationKinexus has an in-house inventory of lysates prepared from 16 human cancer cell lines that have been selected to represent a diversity of tissues,
Kinexus Bioinformatics Corporation is seeking to map and monitor the molecular communications networks of living cells for biomedical research into the diagnosis, prognosis and treatment of human diseases.
More informationLCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
More informationPOLICIES AND CUSTOMS Ph.D. PROGRAM DEPARTMENT OF MOLECULAR & CELLULAR BIOCHEMISTRY UNIVERSITY OF KENTUCKY
- 1 - POLICIES AND CUSTOMS Ph.D. PROGRAM DEPARTMENT OF MOLECULAR & CELLULAR BIOCHEMISTRY UNIVERSITY OF KENTUCKY Revised: March 2010 The following is intended to serve as a guide for graduate students in
More informationWe use Reaxys intensively for hit identification, hit-to-lead and lead optimization.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
More informationScleroderma Foundation Research Grant Application Instructions
1. Application Scleroderma Foundation Research Grant Application Instructions Grant applications that do not meet these guidelines will not be reviewed. Please download our text format version. Grant Application
More informationNIH MENTORED CAREER DEVELOPMENT AWARDS (K01, K08, K23)
NIH MENTORED CAREER DEVELOPMENT AWARDS (K01, K08, K23) Note: the information below is extracted from the current Program Announcements; before applying for a K award you should obtain and read the most
More informationUNIVERSITY GLOBAL PARTNERSHIP NETWORK (UGPN) RESEARCH COLLABORATION FUND 2014 THIRD CALL FOR PROPOSALS
UNIVERSITY GLOBAL PARTNERSHIP NETWORK (UGPN) RESEARCH COLLABORATION FUND 2014 THIRD CALL FOR PROPOSALS SUMMARY The University Global Partnership Network (UGPN) is a preferred partnership network including
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy in Biochemistry FACULTY OF MEDICAL SCIENCE Naresuan University 73 Doctor of Philosophy in Biochemistry The Biochemistry Department at Naresuan University is a leader in lower northern
More informationMovember Clinical Trial Award (CTA)
Movember Clinical Trial Awards Part 1: Overview Participating Organisation (s) Funding Category Description The Movember Foundation and Prostate Cancer Foundation of Australia Movember Clinical Trial Award
More informationFrequently Asked Questions (FAQ)
Frequently Asked Questions (FAQ) Why screen your (therapeutic) antibody for cross-reactivity? Cross-reactivity of therapeutic antibodies leads to adverse effects and might render the antibody unsuitable
More informationDepartment of Biochemistry & Molecular Biology
Department of Biochemistry & Molecular Biology Two-Year Master s Program in Biochemistry & Molecular Biology A four-semester post-baccalaureate program designed to provide advanced training in the biochemical
More informationGrant Writing Essentials Deborah Ann McClellan, Ph.D.
Grant Writing Essentials Deborah Ann McClellan, Ph.D. Research Associate Department of Pharmacology and Molecular Sciences and Division of Biomedical Information Sciences Welch Medical Library Johns Hopkins
More informationCombinatorial Chemistry and solid phase synthesis seminar and laboratory course
Combinatorial Chemistry and solid phase synthesis seminar and laboratory course Topic 1: Principles of combinatorial chemistry 1. Introduction: Why Combinatorial Chemistry? Until recently, a common drug
More informationINTERNATIONALE STICHTING ALZHEIMER ONDERZOEK APPLICATION FELLOWSHIP VISITING PROFESSOR / SENIOR SCIENTIST. GUIDELINES and INSTRUCTIONS
I. Statement of Purpose INTERNATIONALE STICHTING ALZHEIMER ONDERZOEK APPLICATION FELLOWSHIP VISITING PROFESSOR / SENIOR SCIENTIST GUIDELINES and INSTRUCTIONS The Internationale Stichting Alzheimer Onderzoek
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationProgram Announcement. Autism Research Program
Program Announcement for the Defense Health Program Department of Defense Congressionally Directed Medical Research Programs Autism Research Program Pilot Award Funding Opportunity Number: W81XWH-13-ARP-PA
More informationZebrafish Chemical Screens
Zebrafish Chemical Screens 1 Historical look at zebrafish chemical screens 2 The effects of AAF on embryonic development in relation to its carcinogenic role 3 First generation Screens HISAOKA, K. K. (1958).
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationCatalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
More informationProgram Announcement. Neurofibromatosis Research Program
Program Announcement Department of Defense Congressionally Directed Medical Research Programs Neurofibromatosis Research Program New Investigator Award Funding Opportunity Number: W81XWH-13-NFRP-NIA Catalog
More informationSpecific Aims Do s and Don ts
Specific Aims Do s and Don ts John A. Peyman, PhD National Institute of Allergy and Infectious Disease William H. Robinson, MD, PhD Stanford University School of Medicine VA Palo Alto Kelli D. Allen, PhD
More informationSTRUCTURE-GUIDED, FRAGMENT-BASED LEAD GENERATION FOR ONCOLOGY TARGETS
STRUCTURE-GUIDED, FRAGMENT-BASED LEAD GENERATION FOR ONCOLOGY TARGETS Stephen K. Burley Structural GenomiX, Inc. 10505 Roselle Street, San Diego, CA 92121 sburley@stromix.com www.stromix.com Summary Structural
More informationGUIDELINES FOR GRANT APPLICATIONS TO THE NESTLÉ FOUNDATION
GUIDELINES FOR GRANT APPLICATIONS TO THE NESTLÉ FOUNDATION 1. General Information about the Foundation Origin and nature The Nestlé Foundation for the Study of Problems of Nutrition in the World was established
More informationAldosterone and mineralocorticoid receptor (ADMIRE) COST Action BM1301. Tenerife Training school
Aldosterone and mineralocorticoid receptor (ADMIRE) COST Action BM1301 Tenerife Training school February 9 th -13 th, 2015 Mineralocorticoid receptor cell biology and pharmacology The Aldosterone and Mineralocorticoid
More informationMedicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
More informationTECHNICAL INSIGHTS TECHNOLOGY ALERT
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
More informationFLORIDA SEA GRANT COLLEGE PROGRAM Priorities & Funding Opportunities for 2016-2017
FLORIDA SEA GRANT COLLEGE PROGRAM Priorities & Funding Opportunities for 2016-2017 Call for Statements of Interest for Proposed New Applied Research Projects Deadline: February 13, 2015 (4:00 PM Eastern
More informationCystic Fibrosis Foundation PILOT AND FEASIBILITY AWARD
Cystic Fibrosis Foundation PILOT AND FEASIBILITY AWARD Policies and Guidelines CFF Grants and Contracts Office 6931 Arlington Road Bethesda, MD 20814 (301) 841-2637 grants@cff.org I. PILOT AND FEASIBILITY
More informationBROMOscan Quantitative Ligand Binding Assays
BROMOscan Quantitative Ligand Binding Assays Identification of Best In Class Bromodomain Inhibitors Elizabeth Quinn, PhD Director, LeadHunter Discovery Services Outline Introduction Challenges to Epigenetic
More informationA COLLABORATIVE PEDIATRIC CANCER RESEARCH AWARDS PROGRAM 2015 GRANT FUNDING OPPORTUNITY IN PEDIATRIC ONCOLOGY
A COLLABORATIVE PEDIATRIC CANCER RESEARCH AWARDS PROGRAM 2015 GRANT FUNDING OPPORTUNITY IN PEDIATRIC ONCOLOGY LETTER OF INTENT Application Opens September 4, 2014 https://proposalcentral.altum.com/ Due
More informationTips and Guidelines for an NIH Proposal
Tips and Guidelines for an NIH Proposal FORMAT SPECIFICATIONS All file attachments must be in PDF format, and should have descriptive filenames of 50 characters or less, using only standard characters.
More informationConditions for Accreditation as (Basic) Pharmacologist
NEDERLANDSE VERENIGING VOOR FARMACOLOGIE DUTCH PHARMACOLOGICAL SOCIETY Conditions for Accreditation as (Basic) Pharmacologist 1. Introduction The Dutch Pharmacological Society (DPS) is the organization
More informationA career on the science park
A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort
More informationWeill Graduate School of Medical Sciences of Cornell University Program in Pharmacology. Graduate School Curriculum
Weill Graduate School of Medical Sciences of Cornell University Program in Pharmacology Graduate School Curriculum Weill Graduate School of Medical Sciences Partnership between Weill Medical College and
More informationGUIDELINES AND INSTRUCTIONS FOR 2-YEAR GRANT APPLICATIONS
GUIDELINES AND INSTRUCTIONS FOR 2-YEAR GRANT APPLICATIONS IMPORTANT NOTICES Check if you are using the correct grant application form, Standard or Pilot. These documents are updated for each grant cycle.
More informationMaking the most of academic drug target discoveries
Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies
More informationGrant Writing for Research Unfolding the Mystery
Grant Writing for Research Unfolding the Mystery 57 th American Osteopathic Association (AOA) Annual Research Conference Las Vegas, NV Monday, September 30, 2013 8:30 9:00 a.m. Cynthia D. Lamon, Director
More informationApplication Guide. 2015 Global Awards in Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Research
Application Guide 2015 Global Awards in Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Research A Competitive Grants Program Supported by Pfizer www.aspireresearch.org Table of Contents THE ASPIRE
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationwww.iproteos.com Corporate Presentation November, 2013
www.iproteos.com Corporate Presentation November, 2013 The company Iproteos is an early-stage drug development company founded in 2011: Spin-Out from Institute for Research in Biomedicine (IRB Barcelona)
More informationFiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements
Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements PCRP AWARD MECHANISMS WITH EMPHASIS ON RESOURCES Clinical Consortium Award
More informationAMERICAN ACADEMY OF AUDIOLOGY AMERICAN ACADEMY OF AUDIOLOGY FOUNDATION
AMERICAN ACADEMY OF AUDIOLOGY AMERICAN ACADEMY OF AUDIOLOGY FOUNDATION Research Grants in Hearing & Balance Program NEW INVESTIGATOR GUIDELINES Direct Inquiries to molek@audiology.org American Academy
More informationGraduate Studies in Biomedical Sciences
Graduate Studies in Biomedical Sciences The graduate program in Biomedical Sciences is designed to provide a multidisciplinary educational and training environment that will prepare them for independent
More informationSMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationDr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
More informationRT 2 Profiler PCR Array: Web-Based Data Analysis Tutorial
RT 2 Profiler PCR Array: Web-Based Data Analysis Tutorial Samuel J. Rulli, Jr., Ph.D. qpcr-applications Scientist Samuel.Rulli@QIAGEN.com Pathway Focused Research from Sample Prep to Data Analysis! -2-
More informationLRCP Catalyst Grants for Translational Cancer Research Spring 2015 Competition
LRCP Catalyst Grants for Translational Cancer Research Spring 2015 Competition Grant Themes ONLY for: Translational Breast Cancer Research Translational Ovarian Cancer Research Translational Surgical Oncology
More informationThe NIH Roadmap: Re-Engineering the Clinical Research Enterprise
NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before
More informationRequirements and Guidelines
Requirements and Guidelines Doctoral Graduate Program in Microbiology, Immunology, and Molecular Genetics Medical College of Wisconsin Effective January 1, 2005 (version: NOVEMBER 2012) Student and Faculty
More informationApplications are accepted on a rolling basis.
The University of Michigan Health System Peking University Health Science Center Joint Institute for Translational and Clinical Research Clinical Trial Grant Processes Purpose The University of Michigan
More informationDEVELOPING AND TESTING RETRIEVABLE DEVICES AND SCAFFOLDS FOR BETA CELL REPLACEMENT THERAPIES
JDRF REQUESTS LETTERS OF INTENT FOR: DEVELOPING AND TESTING RETRIEVABLE DEVICES AND SCAFFOLDS FOR BETA CELL REPLACEMENT THERAPIES BACKGROUND & PURPOSE One of JDRF s therapeutic goals is to restore beta
More informationStudy Program Handbook Biochemistry and Cell Biology
Study Program Handbook Biochemistry and Cell Biology Bachelor of Science Jacobs University Undergraduate Handbook BCCB - Matriculation Fall 2015 Page: ii Contents 1 The Biochemistry and Cell Biology (BCCB)
More informationUnderstanding the immune response to bacterial infections
Understanding the immune response to bacterial infections A Ph.D. (SCIENCE) DISSERTATION SUBMITTED TO JADAVPUR UNIVERSITY SUSHIL KUMAR PATHAK DEPARTMENT OF CHEMISTRY BOSE INSTITUTE 2008 CONTENTS Page SUMMARY
More informationBiochemistry. Entrance Requirements. Requirements for Honours Programs. 148 Bishop s University 2015/2016
148 Bishop s University 2015/2016 Biochemistry The Biochemistry program at Bishop s is coordinated through an interdisciplinary committee of chemists, biochemists and biologists, providing students with
More informationThe What, When, and How of Grants.gov Finding Your Way with the Electronic Grant Application Process
The What, When, and How of Grants.gov Finding Your Way with the Electronic Grant Application Process Presented by Charles Moore Office of Sponsored Projects Administration cmoore@email.uky.edu What is
More information2015 AriSLA Ice Bucket Call for Clinical Projects
2015 AriSLA Ice Bucket Call for Clinical Projects Deadline: at 1.00 pm, May 12 th, 2015 1. Background AriSLA, Italian Foundation for research on ALS Amyotrophic Lateral Sclerosis, opens its 2015 Call for
More information